Syncona Regulatory News (SYNC)

Syncona Limited - 2017 Dividend Scrip Reference Price

PR Newswire

London, July 31

31 July 2017

Syncona Limited

2017 dividend scrip reference price

The Board of Syncona Limited (the "Company") announces that the scrip reference price for the Company’s 2017 dividend will be £1.7184. This is the higher of (i) the prevailing average of the middle market quotations of the Shares derived from the Daily Official List of the London Stock Exchange for the ex-dividend date, 20 July 2017, and the four subsequent dealing days and (ii) the net asset value per Share of the Company as at 30 June 2017.

[ENDS]

EnquiriesNorthern Trust International Fund Administration Services (Guernsey) LimitedCompany SecretaryTel: 01481 745001 

Copies of this announcement and other corporate information can be found on the company website at:www.synconaltd.com 

About Syncona:

Syncona is a leading FTSE250 healthcare company focused on investing in and building global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders. Our current investment portfolio consists of seven high quality companies in life science and a leading range of fund investments.

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. We are established leaders in gene therapy, cell therapy and advanced diagnostics, and focus on delivering dramatic efficacy for patients in areas of high unmet need.

Our market leading funds portfolio seeks to generate superior returns by investing in long only and alternative investment funds. This represents a productively deployed evergreen funding base which enables us to take a long term approach to investing in life sciences as we target the best new opportunities and support our existing portfolio companies to grow and succeed.

Syncona is aligned with two of the premium charitable funders in UK science, the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both of which are significant shareholders in our business. We make a donation of 0.3% of Net Asset Value to a range of charities each year.